FILE PHOTO: Workers take care of the shipment of Russia's Sputnik V vaccine against the coronavirus disease (COVID-19) at the airport, in Caracas, Venezuela March 29, 2021. REUTERS/Manaure Quintero/File Photo
MOSCOW (Reuters) - Transforming the site of what once was a Soviet-era car factory into a state-of-the-art facility churning out Russia's COVID-19 vaccine Sputnik V was the easy bit.
Making doses in bulk, finding qualified staff and getting equipment have been much bigger headaches for Moscow-based biotech firm R-Pharm and other private Russian companies picked to make the country's flagship shot to fight the pandemic.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
